Varta
← Back to stories

From NDTV

Center-Right Owned by Adani Group (AMG Media)

Johnson & Johnson's Prostate Cancer Drug JNJ-6143 Shrinks Tumours In Early Trial

Johnson & Johnson's Prostate Cancer Drug JNJ-6143 Shrinks Tumours In Early Trial

RSS excerpt

In the early-stage trial, 77% of 31 evaluable patients receiving the 50-milligram dose experienced a PSA decline of at least 50%, while 48% recorded reductions of 90% or more.

✦ Single Source 1 news outlet reporting

Fact-Check & Bias Analysis

Reported by a single newsroom so far. Other outlets have not independently corroborated this story yet.

Coverage Bias Distribution

Based on 1 reporting publisher
Left / Center-Left 0 (0%)
Center 0 (0%)
Center-Right / Right 1 (100%)

Read more news

See all latest stories →